Overall, patients newly prescribed SGLT2i vs DPP-4i were younger, more likely to have obesity, a higher eGFRCr, and to be treated with more than 1 glucose-lowering medication (particularly glucagon-like peptide-1 receptor agonists and insulin), and less likely to have a diagnosis of diabetic nephropathy or CKD (eTables 4-6 in Supplement 1). Here, INS is linked to Obesity.